Nektar Therapeutics operates in the Pharmaceutical preparations sector. Nektar Therapeutics (Nektar) is a clinical-stage biopharmaceutical company developing a pipeline of drug candidates that utilize its PEGylation and polymer conjugate technology platforms. Nektar's product pipeline consists of drug candidates across a range of therapeutic areas, including oncology, pain. In the area of pain, Nektar has a license agreement with AstraZeneca for NKTR-118, an investigational drug candidate, being evaluated in Phase III clinical studies as a once-daily, oral tablet for the treatment of opioid-induced constipation. The agreement includes NKTR-119, an earlier-stage development program that is a co-formulation of NKTR-118 and an opioid. Also in the area of pain, NKTR-181, a mu-opioid analgesic, has completed Phase I development and is being prepared for a Phase II study. In oncology, NKTR-102 is being evaluated in a Phase III clinical study for the treatment of metastatic breast cancer and Phase II studies for the treatment of ovarian and colorectal cancers. In our complete report available for purchase the company is compared to: ISTA Pharmaceuticals, Inc., Hi-Tech Pharmacal Co., Inc. and Jazz Pharmaceuticals, Inc..